ImYoo key facts
as of Oct 2026- Developer of a patient-enabled biodiscovery platform intended to generate scalable, high-fidelity, longitudinal data.
- ImYoo is valued at approximately $7.1M as of Oct 2026 (last reported valuation).
- It has raised $4.1M; the latest was Accelerator/Incubator in Mar 2026.
- Notable investors include Plug and Play Tech Center, Boost VC, Arben Ventures, California Institute of Technology Endowment, Corundum Systems Biology — 11 tracked in total.
- Status: Privately Held (backing).
ImYoo's last reported valuation, Jun 2022. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch ImYoo: the Monday email on marks, rounds and moves
ImYoo funding rounds
No funding rounds for ImYoo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ImYoo
11+ImYoo valuation
ImYoo's last reported valuation was $7.1 million in Jun 2022. No priced round, secondary trade or fund mark has surfaced since.
ImYoo investors
11 investors are on record for ImYoo, including Plug and Play Tech Center, Boost VC, Arben Ventures and California Institute of Technology Endowment.
About ImYoo
Developer of a patient-enabled biodiscovery platform intended to generate scalable, high-fidelity, longitudinal data. The company's platform brings single-cell multi-omic analysis to small blood volumes self-collected at home to better understand disease complexities and develop precision diagnostics and therapies, enabling users to identify critical markers from longitudinal samples and during key disease events, like autoimmune flares or adverse therapeutic side effects.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2021
- Employees
- 5
- Website
- imyoo.health/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.